CA Patent

CA2563164A1 — Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists

Assigned to Pfizer Inc · Expires 2005-10-06 · 21y expired

What this patent protects

This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents an aryl group having from 6 to 10 rin…

USPTO Abstract

This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents an aryl group having from 6 to 10 ring atoms or the like ; X represents an oxygen atom , or the like; Y represents an oxygen atom or the like; and n represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonists activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

Drugs covered by this patent

Patent Metadata

Patent number
CA2563164A1
Jurisdiction
CA
Classification
—
Expires
2005-10-06
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.